Takeaway: Please join me, Rob Metcalf, CEO and Gillian Hooker, Clinical Director at Concert Genetics for a discussion on regulatory and payer trends

Call Now | Bringing Order out of Chaos in the World of Genetic Testing - 20201110 Order Out of Chaos

Since the commercialization of MYGN's BRCA test, the world of genetic testing has rapidly evolved into, well, a bit of a chaotic mess. The combination of an often contradictory or incomplete coding system, limited specialty society guidance and variable clinical utility, just to name a few things, has made it difficult to payers, providers and patients to fully understand for what they are paying and why.

Our friends at Concert Genetics, a company I have had the pleasure of watching grow since its founding in 2010, are bringing some rationality to the complex but promising world of genetic testing. With a leading team of clinicians, researchers, data scientists and software engineers, Concert Genetics launched its proprietary solutions to enable end-to-end genetic testing management; from searching and comparing testing products, to tracking orders and results, to payment integrity and forecasting trends in pricing and utilization.

Please join me, Rob Metcalf and Gillian Hooker on:

CLICK HERE for event details (includes video and materials link)

(Live Video Only)

This will be a wide ranging conversation with Rob and Gillian but we are certain to cover some of my favorite topics:

  • The challenge of bringing order to management of genetic testing
  • CMS's recent regulatory moves
  • CMS v FDA authority to regulate LDTs with FDA as the preferred pathway

We should also touch on how payer attitudes are shifting, the role of cash pay and many more interesting topics. You won't want to miss it.

Call Now | Bringing Order out of Chaos in the World of Genetic Testing - Rob BW 2 700x512

About Rob Metcalf. An experienced software and information services executive, Rob has a passion for building world class companies that use technology to transform entire industries. As CEO of Concert Genetics, Rob is expanding the company’s offerings to advance precision medicine by providing the digital infrastructure for reliable and efficient management of genetic testing.

Prior to Concert Genetics, Rob led cognitive computing company Digital Reasoning as President and Chief Operating Officer, guiding the business through an expansion into financial services and healthcare markets, as well as securing multiple rounds of capital from strategic investors. Prior to Digital Reasoning, Rob held executive positions in Mexico, Canada and the United States with the information services leader LexisNexis. At LexisNexis, Rob oversaw numerous acquisitions as part of the acceleration of the company’s software strategy.

Rob earned his bachelor’s degree in history from Princeton University and his Master of Business Administration from Harvard Business School.

Call Now | Bringing Order out of Chaos in the World of Genetic Testing - Gilian

About Gillian Hooker. Applying her background in molecular and clinical genetics, genetic counseling and behavioral science, Gillian is committed to overcoming the barriers to effective translation of genome science at the patient, provider and system levels. As a researcher in academic and government settings, Gillian has worked with numerous transdisciplinary teams on the front lines of genomics, developing and evaluating methods for delivering genomic information to patients and their providers. Having served as the associate director of a genetic counseling training program, Gillian also brings significant experience in genetics education and outreach.

Gillian completed her doctoral degree in Molecular, Cellular and Developmental Biology at Yale University and her masters degree in Genetic Counseling at the Johns Hopkins School of Public Health / National Human Genome Research Institute Genetic Counseling Training Program. She has been actively involved in the National Society of Genetic Counselors, serving on multiple committees and holding leadership positions in the Familial Cancer and Research Special Interest Groups.

Emily Evans
Managing Director – Health Policy



Twitter
LinkedIn